JP2019522650A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019522650A5 JP2019522650A5 JP2018566470A JP2018566470A JP2019522650A5 JP 2019522650 A5 JP2019522650 A5 JP 2019522650A5 JP 2018566470 A JP2018566470 A JP 2018566470A JP 2018566470 A JP2018566470 A JP 2018566470A JP 2019522650 A5 JP2019522650 A5 JP 2019522650A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- neuropathy
- item
- disease
- damage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 36
- 201000001119 neuropathy Diseases 0.000 claims description 32
- 230000007823 neuropathy Effects 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 24
- 208000024827 Alzheimer disease Diseases 0.000 claims description 20
- 208000028389 Nerve injury Diseases 0.000 claims description 20
- 230000008764 nerve damage Effects 0.000 claims description 20
- 230000006378 damage Effects 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 19
- 210000003169 central nervous system Anatomy 0.000 claims description 16
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 16
- AVCXUODHLRZJJP-UHFFFAOYSA-N 4-[5-(4,7-dimethyl-1-benzofuran-2-yl)-1,2,4-oxadiazol-3-yl]benzoic acid Chemical compound CC1=CC=C(C2=C1C=C(O2)C1=NC(=NO1)C1=CC=C(C(=O)O)C=C1)C AVCXUODHLRZJJP-UHFFFAOYSA-N 0.000 claims description 14
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 14
- 210000001328 optic nerve Anatomy 0.000 claims description 12
- 230000001747 exhibiting effect Effects 0.000 claims description 11
- 230000000926 neurological effect Effects 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 208000010877 cognitive disease Diseases 0.000 claims description 10
- 210000005036 nerve Anatomy 0.000 claims description 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 8
- 208000028698 Cognitive impairment Diseases 0.000 claims description 8
- 208000012902 Nervous system disease Diseases 0.000 claims description 8
- 206010033799 Paralysis Diseases 0.000 claims description 8
- 206010036105 Polyneuropathy Diseases 0.000 claims description 8
- 201000001881 impotence Diseases 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 8
- 230000007824 polyneuropathy Effects 0.000 claims description 8
- 208000020431 spinal cord injury Diseases 0.000 claims description 8
- 230000008733 trauma Effects 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000001757 thermogravimetry curve Methods 0.000 claims description 6
- 239000005711 Benzoic acid Substances 0.000 claims description 5
- 235000010233 benzoic acid Nutrition 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 206010061666 Autonomic neuropathy Diseases 0.000 claims description 4
- 208000006373 Bell palsy Diseases 0.000 claims description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 206010065681 HIV peripheral neuropathy Diseases 0.000 claims description 4
- 206010019468 Hemiplegia Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 206010024229 Leprosy Diseases 0.000 claims description 4
- 206010027926 Monoplegia Diseases 0.000 claims description 4
- 208000026072 Motor neurone disease Diseases 0.000 claims description 4
- 208000025966 Neurological disease Diseases 0.000 claims description 4
- 206010033892 Paraplegia Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 206010037714 Quadriplegia Diseases 0.000 claims description 4
- 206010039966 Senile dementia Diseases 0.000 claims description 4
- 208000036826 VIIth nerve paralysis Diseases 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- 230000007812 deficiency Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 206010027175 memory impairment Diseases 0.000 claims description 4
- 201000005518 mononeuropathy Diseases 0.000 claims description 4
- 208000005264 motor neuron disease Diseases 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000011472 radical prostatectomy Methods 0.000 claims description 4
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 3
- 238000002411 thermogravimetry Methods 0.000 claims description 3
- 230000019771 cognition Effects 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000004580 weight loss Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 230000001272 neurogenic effect Effects 0.000 claims 1
- 102100033909 Retinoic acid receptor beta Human genes 0.000 description 10
- 108091008761 retinoic acid receptors β Proteins 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000013078 crystal Substances 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- 230000014511 neuron projection development Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- -1 Azol-3-yl Chemical group 0.000 description 1
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 description 1
- 102100033912 Retinoic acid receptor gamma Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 231100000878 neurological injury Toxicity 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 108091008726 retinoic acid receptors α Proteins 0.000 description 1
- 108091008760 retinoic acid receptors γ Proteins 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1610867.2A GB201610867D0 (en) | 2016-06-22 | 2016-06-22 | Crystalline forms of a therapeutic compound and processes for their preparation |
| GB1610867.2 | 2016-06-22 | ||
| PCT/EP2017/064802 WO2017220446A1 (en) | 2016-06-22 | 2017-06-16 | Crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid and processes for their preparation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019522650A JP2019522650A (ja) | 2019-08-15 |
| JP2019522650A5 true JP2019522650A5 (cg-RX-API-DMAC7.html) | 2020-07-09 |
| JP7102354B2 JP7102354B2 (ja) | 2022-07-19 |
Family
ID=56895172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018566470A Active JP7102354B2 (ja) | 2016-06-22 | 2017-06-16 | ４－（５－（４，７－ジメチルベンゾフラン－２－イル）－１，２，４－オキサジアゾール－３－イル）安息香酸の結晶形態及びそれらの調製方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10870644B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3475274A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7102354B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109415356B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017279865B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3025858C (cg-RX-API-DMAC7.html) |
| GB (1) | GB201610867D0 (cg-RX-API-DMAC7.html) |
| IL (1) | IL263786B (cg-RX-API-DMAC7.html) |
| MX (1) | MX387013B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017220446A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201610867D0 (en) | 2016-06-22 | 2016-08-03 | King S College London | Crystalline forms of a therapeutic compound and processes for their preparation |
| GB201907647D0 (en) * | 2019-05-30 | 2019-07-17 | King S College London | Therapeutic methods |
| CN111238897B (zh) * | 2020-02-18 | 2023-03-28 | 上海市皮肤病医院 | 生物标本的处理方法与处理剂 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0842923B1 (en) | 1995-06-07 | 2006-03-01 | Nippon Shinyaku Company, Limited | Pyrrole derivatives and medicinal composition |
| JP3964478B2 (ja) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
| JP3995716B2 (ja) * | 1996-03-18 | 2007-10-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 縮合環含有カルボン酸誘導体 |
| JPH10158192A (ja) | 1996-10-03 | 1998-06-16 | Eisai Co Ltd | 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物 |
| GB9907461D0 (en) | 1999-03-31 | 1999-05-26 | King S College London | Neurite regeneration |
| WO1999020309A1 (en) | 1997-10-22 | 1999-04-29 | Eisai Co., Ltd. | Retinoic acid agonists as preventive and therapeutic agents for nephritis |
| CN1638776A (zh) | 2001-06-08 | 2005-07-13 | 西托维亚公司 | 取代的3－芳基－5－芳基－[1,2,4]－噁二唑和类似物 |
| JP2003081832A (ja) | 2001-06-26 | 2003-03-19 | Takeda Chem Ind Ltd | レチノイド関連受容体機能調節剤 |
| WO2003062230A1 (en) | 2002-01-21 | 2003-07-31 | Eisai Co., Ltd. | Conbinatorial library of heterocycle compounds |
| KR20050033070A (ko) | 2002-08-09 | 2005-04-08 | 아스트라제네카 에이비이 | 메타보트로픽 글루타메이트 수용체-5의 조절제로서[1,2,4]옥사디아졸 |
| JP4851933B2 (ja) | 2003-04-11 | 2012-01-11 | ピーティーシー セラピューティクス，インコーポレーテッド | １，２，４−オキサジアゾール安息香酸化合物ならびにナンセンス抑制及び疾患の治療のためのその使用 |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| WO2006044503A2 (en) | 2004-10-13 | 2006-04-27 | Ptc Therapeutics, Inc. | Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases |
| US20090176837A1 (en) | 2005-07-12 | 2009-07-09 | Sony Corporation | Compounds with activity at retinoic acid receptors |
| US20100222304A1 (en) | 2006-11-02 | 2010-09-02 | Lillian W Chiang | Methods of Treating Neuropathic Pain by Modulation of Glycogenolysis or Glycolysis |
| JP2011523997A (ja) | 2008-05-30 | 2011-08-25 | フォスター ホイーラー エナージア オサケ ユキチュア | 酸素燃焼によって動力を発生させるための方法及び装置 |
| EP2314569A1 (en) * | 2009-10-22 | 2011-04-27 | Merck Patent GmbH | Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof |
| WO2011072281A1 (en) | 2009-12-11 | 2011-06-16 | Ptc Therapeutics, Inc. | Methods for treating methylmalonic acidemia |
| US9994559B2 (en) | 2014-12-17 | 2018-06-12 | King's College London | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists |
| GB201610867D0 (en) | 2016-06-22 | 2016-08-03 | King S College London | Crystalline forms of a therapeutic compound and processes for their preparation |
-
2016
- 2016-06-22 GB GBGB1610867.2A patent/GB201610867D0/en not_active Ceased
-
2017
- 2017-06-16 MX MX2018016250A patent/MX387013B/es unknown
- 2017-06-16 EP EP17733396.0A patent/EP3475274A1/en active Pending
- 2017-06-16 JP JP2018566470A patent/JP7102354B2/ja active Active
- 2017-06-16 WO PCT/EP2017/064802 patent/WO2017220446A1/en not_active Ceased
- 2017-06-16 AU AU2017279865A patent/AU2017279865B2/en active Active
- 2017-06-16 US US16/311,318 patent/US10870644B2/en active Active
- 2017-06-16 CA CA3025858A patent/CA3025858C/en active Active
- 2017-06-16 CN CN201780038472.8A patent/CN109415356B/zh active Active
-
2018
- 2018-12-18 IL IL263786A patent/IL263786B/en unknown
-
2020
- 2020-12-02 US US17/109,758 patent/US11584741B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022209232B2 (en) | C17, C20, and C21 substituted neuroactive steroids and their methods of use | |
| JP6843135B2 (ja) | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物 | |
| JP2011116780A5 (cg-RX-API-DMAC7.html) | ||
| JP2020531448A (ja) | 新規なスルホンアミドカルボキサミド化合物 | |
| JP2019522650A5 (cg-RX-API-DMAC7.html) | ||
| JP2708736B2 (ja) | ピリジン誘導体の製造方法 | |
| TW202110457A (zh) | 神經活性類固醇及其組合物 | |
| TWI835884B (zh) | 神經活性類固醇及其使用方法 | |
| TW200819127A (en) | Novel receptor antagonists and their methods of use | |
| JP2021504443A (ja) | スルホンピリジンアルキルアミド置換ヘテロアリール化合物 | |
| TW202233198A (zh) | 神經活性類固醇及其組合物 | |
| CN1227233C (zh) | 纯晶形的5－氯－3－(4－甲磺酰基苯基)－6′－甲基－[2,3′]联吡啶及其合成方法 | |
| JP2017519015A5 (cg-RX-API-DMAC7.html) | ||
| KR20140006768A (ko) | Lsd1의 아릴사이클로프로필아민 기반 디메틸라아제 억제제 및 이의 의학적 이용 | |
| CA2916500A1 (en) | Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors | |
| TW202114695A (zh) | 用於治療cns病症之組合物及方法 | |
| JP2021501151A5 (cg-RX-API-DMAC7.html) | ||
| TW202235089A (zh) | 用於治療ｃｎｓ病症的組成物及方法 | |
| JP2014506602A5 (cg-RX-API-DMAC7.html) | ||
| JP2024160326A (ja) | Ｅａａｔ２活性化因子およびその使用方法 | |
| JP2010535200A5 (cg-RX-API-DMAC7.html) | ||
| JP6985271B2 (ja) | アルキニルジヒドロキノリンスルホンアミド化合物 | |
| JP2010514725A5 (cg-RX-API-DMAC7.html) | ||
| TW201211006A (en) | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | |
| MX2014003960A (es) | Peptidomimeticos fijados a plantilla como inhibidores de receptor de formil-peptido 1. |